Wellington Management Group LLP Decreases Stake in Replimune Group, Inc. (NASDAQ:REPL)

Wellington Management Group LLP decreased its position in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 40.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 242,398 shares of the company's stock after selling 163,118 shares during the period. Wellington Management Group LLP owned approximately 0.35% of Replimune Group worth $2,657,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. grew its position in Replimune Group by 12.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company's stock worth $5,313,000 after purchasing an additional 52,498 shares during the period. LMR Partners LLP raised its holdings in Replimune Group by 145.8% in the 3rd quarter. LMR Partners LLP now owns 82,479 shares of the company's stock worth $904,000 after purchasing an additional 48,920 shares during the period. Millennium Management LLC boosted its position in Replimune Group by 575.1% during the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company's stock worth $28,062,000 after purchasing an additional 2,656,173 shares in the last quarter. Cubist Systematic Strategies LLC grew its holdings in Replimune Group by 282.2% in the second quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company's stock valued at $650,000 after purchasing an additional 53,313 shares during the period. Finally, Acadian Asset Management LLC increased its position in shares of Replimune Group by 63.2% in the second quarter. Acadian Asset Management LLC now owns 185,516 shares of the company's stock valued at $1,668,000 after buying an additional 71,867 shares in the last quarter. Hedge funds and other institutional investors own 92.53% of the company's stock.

Replimune Group Trading Down 0.5 %

Shares of REPL traded down $0.06 during midday trading on Wednesday, reaching $11.66. The company had a trading volume of 861,266 shares, compared to its average volume of 1,045,915. Replimune Group, Inc. has a 1-year low of $4.92 and a 1-year high of $17.00. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. The firm has a 50 day simple moving average of $12.22 and a 200-day simple moving average of $10.62. The stock has a market cap of $797.74 million, a PE ratio of -3.82 and a beta of 1.26.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.07. Research analysts forecast that Replimune Group, Inc. will post -2.91 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on REPL shares. Roth Mkm began coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They issued a "buy" rating and a $17.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $17.00 price target on shares of Replimune Group in a research note on Friday, November 22nd. BMO Capital Markets increased their target price on Replimune Group from $14.00 to $18.00 and gave the company an "outperform" rating in a report on Friday, November 22nd. Jefferies Financial Group lifted their price target on Replimune Group from $16.00 to $19.00 and gave the stock a "buy" rating in a research note on Wednesday, December 4th. Finally, JPMorgan Chase & Co. raised their price objective on Replimune Group from $14.00 to $17.00 and gave the company an "overweight" rating in a report on Tuesday, September 24th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $17.29.

Insider Activity

In other news, CEO Sushil Patel sold 10,000 shares of the company's stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the transaction, the chief executive officer now directly owns 202,014 shares in the company, valued at approximately $2,509,013.88. This represents a 4.72 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the sale, the insider now owns 109,885 shares of the company's stock, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 8.80% of the company's stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.